Journal of thrombosis and haemostasis : JTH · 2025
Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alsuliman Tamim, Chalayer Emilie, Stocker Nicolas, Garidi Reda, Crichi Benjamin, Marjanovic Zora, Frere Corinne
Аннотация
BACKGROUND: Tranexamic acid (TXA) is commonly used off-label as an adjunct to prophylactic platelet transfusion to prevent bleeding in patients with hematological malignancies undergoing intensive chemotherapy or hematopoietic stem cell transplantation.
OBJECTIVES: We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of TXA vs placebo for the primary prevention of bleeding in patients with hematological malignancies experiencing hypoproliferative thrombocytopenia.
METHODS: Embase, MEDLINE, and CENTRAL were searched from inception until June 30, 2025. The primary efficacy outcome was the incidence of World Health Organization grade of ≥2 bleeding. The secondary efficacy outcome was the mean number of platelet transfusions per participant in each group. Safety outcomes included the incidence of thrombotic events, veno-occlusive disease, and all-cause mortality. Random-effects meta-analyses were performed for the outcomes of interest.
RESULTS: Two RCTs enrolling 946 patients were included. Compared with placebo, TXA did not reduce the risk of World Health Organization grade of ≥2 bleeding (relative risk [RR], 0.91; 95% CI, 0.77-1.07) or the mean number of platelet transfusions per participant (standardized mean difference, 0.00; 95% CI, -0.12 to 0.13). The risk of thrombotic events (RR, 1.00; 95% CI, 0.43-2.32), veno-occlusive disease (RR, 1.49; 95% CI, 0.42-5.25), and all-cause mortality (RR, 1.26; 95% CI, 0.78-2.02) was similar in the 2 groups. Trial sequential analysis for the primary outcome indicated that the current evidence is conclusive, suggesting the futility of additional RCTs.
CONCLUSIONS: TXA did not provide sufficient benefits to justify its routine use for preventing bleeding in this patient population.
OBJECTIVES: We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of TXA vs placebo for the primary prevention of bleeding in patients with hematological malignancies experiencing hypoproliferative thrombocytopenia.
METHODS: Embase, MEDLINE, and CENTRAL were searched from inception until June 30, 2025. The primary efficacy outcome was the incidence of World Health Organization grade of ≥2 bleeding. The secondary efficacy outcome was the mean number of platelet transfusions per participant in each group. Safety outcomes included the incidence of thrombotic events, veno-occlusive disease, and all-cause mortality. Random-effects meta-analyses were performed for the outcomes of interest.
RESULTS: Two RCTs enrolling 946 patients were included. Compared with placebo, TXA did not reduce the risk of World Health Organization grade of ≥2 bleeding (relative risk [RR], 0.91; 95% CI, 0.77-1.07) or the mean number of platelet transfusions per participant (standardized mean difference, 0.00; 95% CI, -0.12 to 0.13). The risk of thrombotic events (RR, 1.00; 95% CI, 0.43-2.32), veno-occlusive disease (RR, 1.49; 95% CI, 0.42-5.25), and all-cause mortality (RR, 1.26; 95% CI, 0.78-2.02) was similar in the 2 groups. Trial sequential analysis for the primary outcome indicated that the current evidence is conclusive, suggesting the futility of additional RCTs.
CONCLUSIONS: TXA did not provide sufficient benefits to justify its routine use for preventing bleeding in this patient population.